Lenacapavir (LEN) Disrupts HIV-1 Assembly and Induces Giant, Noninfectious Virus-Like Particles (IMAGE)
Caption
Combining single-particle mass photometry (top) and transmission electron microscopy (bottom), researchers show how the antiretroviral drug lenacapavir (LEN) interferes with the late stages of HIV-1 particle formation. Under normal conditions (LEN 0 nM, blue), HIV-1 forms uniform, spherical particles roughly 100 to 130 nanometers in diameter. When treated with LEN (60 nM, orange), the drug binds to Gag, a protein that helps build HIV-1 particles, and disrupts orderly assembly, drastically reducing the number of normal-sized particles. Electron microscopy reveals that LEN instead triggers the formation of enlarged, irregularly shaped "LEN-induced virus-like particles" (LENiVLPs) exceeding 200 nanometers in diameter. Although these giant particles contain viral proteins (Gag and envelope glycoproteins) and can still attach to and fuse with host cells, structural defects prevent them from replicating, rendering them noninfectious.
Credit
Adapted from Amesimeku et al., Proceedings of the National Academy of Sciences (PNAS), 2026, https://doi.org/10.1073/pnas.2609634123, with permission from the authors. Originally published under the CC BY-NC-ND 4.0 license.
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND